The scoreboard, honestly: the hard targets, how often each one is actually looked at,
and the quiet human signals that never make it onto a dashboard.
Portfolio Return on Investment (ROI)
The financial return generated by products launched from the R&D portfolio you oversee, relative to the R&D spend.
Target · Achieve a minimum of 3x R&D spend over a 5-year post-launch period for the overall portfolio.If we spent £100M on R&D for a portfolio of products, we'd expect those products to generate at least £300M in profit within five years of launch. You'll track this at a portfolio level, not just per project.
New Product Vitality Index
The percentage of total corporate revenue derived from products launched within the last 3-5 years, indicating the health of our innovation pipeline.
Target · Maintain or increase the New Product Vitality Index to over 25% of total revenue.If our total revenue is £500M, and £125M comes from products launched in the last three years, that's a 25% vitality index. You'll influence this by optimising project selection and delivery.
Strategic Alignment of R&D Portfolio
The proportion of the total R&D budget allocated to projects that directly support the top three corporate strategic initiatives.
Target · Ensure >90% of the annual R&D budget is allocated to projects clearly aligned with our top three corporate strategic initiatives.If our strategic goals are 'Sustainable Materials', 'Digital Health Solutions', and 'Emerging Market Expansion', you'll show that nearly all R&D spend directly contributes to one of those areas, not pet projects.
Overall R&D Project Success Rate
The percentage of projects within the R&D portfolio that are delivered within +/- 10% of their approved budget, timeline, and scope.
Target · Achieve an 85% success rate for projects under PMO governance.Out of 100 active R&D projects, 85 should hit their targets. This isn't about individual project management, but about the systemic improvements your PMO brings.
PMO Operational Efficiency
Reduction in administrative overhead and cycle time for key project management processes (e.g., gate review preparation, budget approval, risk logging).
Target · Reduce average cycle time for critical PM processes by 20% year-on-year.If a typical gate review preparation used to take 40 hours of a PM's time, you'll aim to get that down to 32 hours through better templates, automation, and clear guidelines.
R&D Methodology Adoption & Adherence
The consistent and effective application of our defined R&D project management methodologies (e.g., Stage-Gate, Design Controls) across all global teams.
- Feedback from internal audits showing high compliance, consistent quality of Design History Files (DHFs) across projects, positive feedback from R&D teams on the clarity and usefulness of PMO processes, and a reduction in 'workarounds' or 'shadow processes'.
Talent Development & PM Capability
The growth and professional development of our R&D project management talent, ensuring we have a strong pipeline of skilled PMs.
- Increased internal promotion rates for PM roles, positive feedback from direct reports and mentees on career development support, clear and recognised career pathways for PMs, and a demonstrable improvement in the average competency level of our project management staff.
Executive & Business Unit Confidence
The level of trust and confidence that the C-suite and Business Unit Heads have in the R&D PMO's ability to deliver on strategic objectives.
- Proactive consultation by executives on strategic R&D decisions, consistent positive feedback in executive forums, the PMO being seen as a 'go-to' resource for complex programme challenges, and minimal escalations related to project management issues.
Proactive Risk Management Maturity
The organisation's ability to anticipate, identify, and mitigate portfolio-level risks before they become critical issues.
- A demonstrable reduction in 'surprise' project failures or major delays, early identification of systemic risks across the portfolio, effective implementation of mitigation strategies, and the PMO being seen as a key partner in de-risking the overall R&D investment.